Revenue up 18.2% but development margin slid to 28.3% from 33.5%

What changed

Revenue rose 18.2% to NZ$151.6m on 588 occupation right sales (HY23: 483), but profitability moved the other way. PBT fell 5.7% to NZ$120.8m and reported NPAT fell 23.2% to NZ$102.2m. The NPAT decline materially overstates the operating slippage: current tax expense of about NZ$18.6m replaced a prior tax benefit, lifting the effective tax rate to 15.4% from 3.9% and opening a 17.5pp gap between PBT and NPAT growth. Management's own underlying profit measure was NZ$89.9m, up 3%. Development margin compressed to 28.3% from 33.5%. Operating cash flow improved 30.7% to NZ$191.6m, but cash on hand fell 40% to NZ$21.0m and gross borrowings rose 19% to NZ$1.5b, taking net debt to roughly NZ$1.52b from NZ$1.26b. Total assets expanded 16.9% to NZ$7.36b. The interim dividend was held flat at 11.3c per share.

What matters

• Development margin compression is the single most important datapoint. A 520bps fall to 28.3% while sales volumes grew 22% suggests the pricing/cost mix has moved against Summerset, not just a one-period mix quirk. It is the reason PBT declined despite double-digit revenue growth.
• PBT, not NPAT, is the cleaner read. The 5.7% PBT decline is a more honest description of operating trajectory than the 23.2% NPAT fall, which is largely a tax-line swing from a prior-period benefit.
• Leverage is trending the wrong way. Net debt rose about NZ$260m year on year, cash fell 40%, and equity grew 16.9% — the balance sheet is expanding to fund development, but net debt is growing faster than cash and the ROE print on the analytical pass slipped to 7.6% from 11.5%.

Expectations

No quantitative forward work target or earnings guidance was disclosed in the extracted material. On shape, HY23 represented only 30.5% of FY23 NPAT and 47.1% of FY23 revenue — the FY pattern is heavily second-half weighted, so HY24's NPAT cannot be straight-line doubled. Annualising HY24 revenue gives NZ$303.3m, about 11.4% above FY23's NZ$272.2m, so the top-line run rate is tracking ahead of last year. Whether that translates into FY24 earnings growth depends almost entirely on whether development margin stabilises in H2, which the release does not address.

Quality of result

Mixed. On the positive side, operating cash flow growth (+30.7%) exceeded revenue growth, capex fell modestly to NZ$27.4m, and pre-lease free cash flow rose to NZ$164.2m from NZ$117.2m — OCF-to-NPAT of 160.7% is flattered by the tax swing but still indicates healthy cash generation. Receivable days edged down to 55.6 from 57.5. On the negative side, the underlying earnings story is weaker than the revenue headline: development margin compression is a unit-economics issue rather than a timing one, and the underlying profit figure of NZ$89.9m (up only 3%) is the more telling measure. The cash build is also being recycled straight into the development pipeline — gross borrowings are up NZ$246m and cash is down — so balance-sheet-assisted growth is a real part of the result.

Unresolved

• What specifically drove development margin from 33.5% to 28.3% — site mix, build cost inflation, pricing, or settlement timing?
• Where is the full IFRS-to-underlying profit reconciliation? A NZ$89.9m underlying figure against NZ$102.2m reported NPAT is disclosed without the bridge in the extracted material.
• What is the forward occupation right sales book, and does it support a return to stronger H2 margin?
• How is the net debt path expected to evolve against the scheduled development programme, and what are the applicable covenants?
• Is the flat 11.3c interim dividend signalling a deliberate pause, given the payout ratio on NPAT rose to 26.0% from 19.7%?

This briefing cannot assess EBITDA trends, segment-level profitability, forward sales pipeline, or net-debt-to-earnings leverage, because none of those figures were disclosed in the extracted material.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.